Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

被引：0
|
作者：
Gizem Oner
Semen Önder
Hüseyin Karatay
Naziye Ak
Mustafa Tükenmez
Mahmut Müslümanoğlu
Abdullah İğci
Ahmet Dincçağ
Vahit Özmen
Adnan Aydiner
Ekrem Yavuz
Neslihan Cabioğlu
机构：
[1] Istanbul University,Department of General Surgery, Istanbul Faculty of Medicine
[2] Antwerp University Hospital,Multidisciplinary Oncologic Centre Antwerp (MOCA)
[3] University of Antwerp,Center for Oncological Research (CORE)
[4] Istanbul University,Department of Pathology, Istanbul Faculty of Medicine
[5] Istanbul University,Department of Medical Oncology, Institute of Oncology
来源：
World Journal of Surgical Oncology | / 19卷
关键词：
Triple-negative breast cancer; PD-L1 expression; Prognosis; Neoadjuvant chemotherapy response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer
    Wang, Han
    Ding, Xiao-Hong
    Liu, Cheng-Lin
    Xiao, Yi
    Shui, Ruo-Hong
    Li, Yan-Ping
    Chen, Chen
    Yang, Wen-Tao
    Shao, Zhi-Ming
    Jiang, Yi-Zhou
    CANCER RESEARCH, 2024, 84 (09)
  • [42] JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
    Chen, Meixuan
    Pockaj, Barbara
    Andreozzi, Mariacarla
    Barrett, Michael T.
    Krishna, Sri
    Eaton, Seron
    Niu, Ruifang
    Anderson, Karen S.
    CLINICAL BREAST CANCER, 2018, 18 (05) : E1205 - E1215
  • [43] Transcription factor T-bet and PD-L1 expression in tumor microenvironment of triple-negative breast cancer
    Mori, H.
    Kubo, M.
    Kai, M.
    Kurata, K.
    Kawaji, H.
    Kaneshiro, K.
    Motoyama, Y.
    Kuroki, R.
    Yamada, M.
    Nishimura, R.
    Okido, M.
    Oda, Y.
    Nakamura, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Correlations between PD-L1 Expression and Tumor Infiltrating Lymphocytes and Molecular Subtype in Triple-Negative Breast Cancer
    Ma, Xiaoxi
    Chen, Chen
    Yang, Wentao
    Shui, Ruohong
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 159 - 160
  • [45] Correlations between PD-L1 Expression and Tumor Infiltrating Lymphocytes and Molecular Subtype in Triple-Negative Breast Cancer
    Ma, Xiaoxi
    Chen, Chen
    Yang, Wentao
    Shui, Ruohong
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 159 - 160
  • [46] Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
    Casadevall, David
    Li, Xiaotong
    Powles, Ryan L.
    Wali, Vikram B.
    Buza, Natalia
    Pelekanou, Vasiliki
    Dhawan, Arjun
    Foldi, Julia
    Szekely, Borbala
    Lopez-Giraldez, Francesc
    Hatzis, Christos
    Pusztai, Lajos
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 6
  • [47] PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer
    Akiki, Mira
    Haddad, Fady Gh
    Kourie, Hampig Raphael
    Khaddage, Abir
    Smayra, Viviane Track
    BIOMARKERS IN MEDICINE, 2019, 13 (18) : 1539 - 1541
  • [48] Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constatin, Guillaume
    Ilie, Alis
    Beltjens, Francoise
    Ladoire, Sylvain
    Desmoulins, Isabelle
    Hennequin, Audrey
    Bertaut, Aurelie
    Coutant, Charles
    Causeret, Sylvain
    Ghozali, Niama
    Coudert, Bruno
    Arnould, Laurent
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [49] Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
    Sohn, J.
    Do, K. A.
    Liu, S.
    Chen, H.
    Mills, G. B.
    Hortobagyi, G. N.
    Meric-Bernstam, F.
    Gonzalez-Angulo, A. M.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2522 - 2526
  • [50] Pathologic and immunohistochemical prognostic score in residual triple-negative breast cancer after neoadjuvant chemotherapy
    Ilie, S. M.
    Arnould, L.
    Briot, N.
    Desmoulins, I.
    Hennequin, A.
    Kaderbhai, C.
    Bertaut, A.
    Coutant, C.
    Causeret, S.
    Loustalot, C.
    Ilie, A.
    Derangere, V.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S432 - S432
12345